Arrowhead Pharmaceuticals (BSP:A2RR34) Cyclically Adjusted FCF per Share: R$-0.61 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:A2RR34 Arrowhead Pharmaceuticals Inc BSP:A2RR34
19 GF Score
Price R$54.48
GF Value R$33.91
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share?

Arrowhead Pharmaceuticals BSP:A2RR34 19 Cyclically Adjusted FCF per Share is R$-0.61 as of Jun. 2026. GuruFocus rates BSP:A2RR34 with a GF Score™ of 19/100 and a GF Value™ of R$33.91 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Arrowhead Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was R$-6.480. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$-0.61 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -19.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -13.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Arrowhead Pharmaceuticals was 35.20% per year. The lowest was -32.00% per year. And the median was 18.85% per year.

As of today (2026-09-11), Arrowhead Pharmaceuticals's current stock price is R$54.48. Arrowhead Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was R$-0.61. Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Arrowhead Pharmaceuticals  (BSP:A2RR34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arrowhead Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.61

BSP:A2RR34 vs HALO, CORT, MDGL: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


BSP:A2RR34
19GF Score
Arrowhead Pharmaceuticals Inc BSP:A2RR34
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arrowhead Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-6.48/333.9520*333.9520
=-6.480

Current CPI (Jun. 2026) = 333.9520.

Arrowhead Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.646 241.428 -0.894
201612 0.221 241.432 0.306
201703 -0.657 243.801 -0.900
201706 -0.510 244.955 -0.695
201709 -0.390 246.819 -0.528
201712 -0.653 246.524 -0.885
201803 -0.617 249.554 -0.826
201806 -0.629 251.989 -0.834
201809 -0.158 252.439 -0.209
201812 6.807 251.233 9.048
201903 -0.775 254.202 -1.018
201906 0.285 256.143 0.372
201909 0.244 256.759 0.317
201912 -1.177 256.974 -1.530
202003 -1.499 258.115 -1.939
202006 -1.812 257.797 -2.347
202009 -0.694 260.280 -0.890
202012 -2.163 260.474 -2.773
202103 13.927 264.877 17.559
202106 -1.620 271.696 -1.991
202109 -1.632 274.310 -1.987
202112 -3.629 278.802 -4.347
202203 2.673 287.504 3.105
202206 -3.740 296.311 -4.215
202209 -5.024 296.808 -5.653
202212 -5.660 296.797 -6.369
202303 -2.841 301.836 -3.143
202306 -3.056 305.109 -3.345
202309 -4.138 307.789 -4.490
202312 -8.507 306.746 -9.262
202403 -5.108 312.332 -5.462
202406 -5.632 314.175 -5.987
202409 -7.192 315.301 -7.617
202412 -7.515 315.605 -7.952
202503 19.471 319.799 20.333
202506 -6.266 322.561 -6.487
202509 0.506 324.800 0.520
202512 0.439 324.054 0.452
202603 3.007 330.213 3.041
202606 -6.480 333.952 -6.480

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of R$-0.61 mean?
Arrowhead Pharmaceuticals (BSP:A2RR34) has a Cyclically Adjusted FCF per Share of R$-0.61 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Arrowhead Pharmaceuticals' current Cyclically Adjusted FCF per Share is R$-0.61. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Cyclically Adjusted FCF per Share compare to HALO and CORT?
Arrowhead Pharmaceuticals' Cyclically Adjusted FCF per Share of R$-0.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Cyclically Adjusted FCF per Share is R$-0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (BSP:A2RR34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$33.91, compared to a current price of R$54.48 — trading 60.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is R$-0.61. Arrowhead Pharmaceuticals' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (BSP:A2RR34), the current Cyclically Adjusted FCF per Share is R$-0.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (BSP:A2RR34) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of R$54.48 is trading 60.7% above its estimated GF Value™ of R$33.91. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BSP:A2RR34:

  • Cyclically Adjusted FCF per Share: R$-0.61
  • GF Value™: R$33.91 vs. price of R$54.48 (60.7% above fair value)
  • GF Score™: 19/100 with 6 warning signs

No single metric tells the full story. See the BSP:A2RR34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arrowhead Pharmaceuticals Business Description

Other Exchanges ARWR:USA0HI3:UKHDP1:Germany
Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
19GF Score

Get the complete analysis for BSP:A2RR34

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$54.48
Price
R$33.91
GF Value